Researchers at University College London explored how red light at a wavelength of 670 nanometers influences glucose processing in the human body. The study, published in the Journal of Biophotonics, examined whether photobiomodulation can alter blood sugar dynamics without medications. The investigation focused on whether light energy could modulate cellular metabolism in a way that helps manage glucose levels over time.
In total, thirty volunteers took part in the trial. They were split into two groups: one received exposure to red light at 670 nanometers, while the other acted as the control group with no targeted light treatment. Following a period of photobiomodulation, researchers tracked blood glucose levels across all participants to assess any differential effects induced by the light intervention.
Results indicated that individuals in the light-exposed group exhibited lower average blood sugar concentrations, with a reduction of roughly 27.7 percent compared to baseline measurements. The team explained that red light in this specific wavelength can interact with cellular energy hubs known as mitochondria. By stimulating mitochondrial activity, cells receive more energy to drive essential biological processes, potentially influencing how glucose is utilized.
To unpack this mechanism, mitochondria convert nutrients from glucose into adenosine triphosphate (ATP), the primary energy currency of cells. ATP supports muscle function, nerve signaling, and many other physiological activities. The study noted that heightened mitochondrial activity corresponded with increased glucose processing, which contributed to the observed drop in circulating glucose levels among participants in the experimental group.
While these findings are preliminary, researchers are optimistic about the potential of noninvasive, drug-free approaches to support diabetes management. Continued investigation could clarify the durability of the effect, optimal exposure parameters, and who might benefit most from this kind of light-based therapy. The goal is to add a safe, adjunctive option to the broader diabetes care toolkit, complementing lifestyle strategies and existing medical treatments.
Looking ahead, scientists emphasize the importance of replication and long-term studies to determine practical clinical applications. If confirmed, photobiomodulation with 670 nm red light could become part of a comprehensive approach to stabilize glycemic control for people with diabetes.
Earlier work in the field has suggested that enhancing cellular energy pathways may improve responses to various diabetes interventions, hinting at a broader potential for light-based strategies in metabolic health. As the body of evidence grows, clinicians and researchers will better understand how to harness this technology while ensuring safety, accessibility, and efficacy across diverse patient populations.